ClinicalTrials.gg
TerminatedNCT01555710Updated Oct 1, 2026

Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)

A Phase 3 interventional study of Carboplatin and Palifosfamide-tris in Extensive-Stage Small Cell Lung Cancer, sponsored by Alaunos Therapeutics. Terminated at 79 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Alaunos Therapeutics · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
Sponsor closed enrollment in April 2013 following a change in the palifosfamide development plan (business decision), not for safety reasons. Enrolled participants continued treatment and were followed for survival
Updated Oct 1, 2026Now TerminatedEligibility revised+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
188
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 631 studies in Small Cell Lung Carcinoma with a site in United States — 112 open to participants now, 183 under way, 26 of them phase 3. Small Cell Lung Carcinoma · United States.

Enrollment
112th of 552
188 · median 55
Started
2012
with 14 others
Phase 3
50 of 631
11 open now
Registered
239th of 631
by date

Among the 631 studies in Small Cell Lung Carcinoma with a site in United States, this one is the 112th largest by enrollment of the 552 interventional ones that give a count, is one of 15 that started in 2012, is one of 50 in phase 3, and was the 239th registered.

Small Cell Lung Carcinoma

1,303 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

112 of the 631 studies in Small Cell Lung Carcinoma with a site in United States are open now. Recruiting first, the newest first:

107 more — sign in →

All 112 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 176 (66%) set no upper age limit and 65 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 631 studies in Small Cell Lung Carcinoma with a site in United States, or all of them as a file.
02

Study summary

This is a multinational, multicenter, randomized controlled, open-label, adaptive study to evaluate the efficacy of palifosfamide-tris, carboplatin and etoposide (PaCE) chemotherapy in chemotherapy-naive subjects with extensive-stage small cell lung cancer (SCLC). Eligible subjects will be stratified according to age, gender, and Eastern Cooperative Oncology Group (ECOG) performance status, and randomized in a 1:1 ratio to receive either PaCE or carboplatin and etoposide (CE) chemotherapy.

The study design uses an adaptive group sequential approach with sample size re-estimation at the interim analysis.

Secondary efficacy endpoints include objective response rate (ORR), progression-free survival (PFS), duration of response and changes in quality of life (QOL) and disease-related symptoms. Tumor-related endpoints will be assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 guidelines.

The safety of study treatments will be assessed by the frequency and severity of adverse events as determined by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03. To provide an initial confirmation of safety, an early interim analysis of safety data only will be performed.

An independent Data Monitoring Committee (DMC) will be convened to assess the safety and efficacy of the study interventions and to monitor the overall conduct of the clinical trial.

03

Conditions studied

  • Extensive-Stage Small Cell Lung Cancer
04

Who can participate

The criteria were revised on the registry on Oct 1, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented extensive-stage small cell lung cancer.
  • Patient has received no prior chemotherapy, therapy, or radiotherapy for lung cancer.
  • (ECOG) performance status of 0, 1 or 2
  • Adequate bone marrow and organ function based on the results of protocol- specified laboratory tests.
  • Male and female patients must agree to use a highly reliable method of during study participation.
  • Able to provide

Exclusion criteria

Exclusion Criteria:

  • Previously untreated (non-irradiated), symptomatic .
  • Known allergy to any of the study drugs or their .
  • Any unstable or concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a patient and/or their compliance with the protocol, based on screening tests, physical examination and medical history (as specifically defined in the clinical protocol).
  • Any other than small cell lung cancer within the last 5 years prior to randomization, with the exception of cervical carcinoma in situ, nonmelanoma skin cancer, or superficial bladder tumors (Ta, Tis, or T1) that have been successfully and curatively treated with no evidence of recurrent or residual disease. (Exception: Subjects with a history of malignancy other than small cell lung cancer may be enrolled after consultation with the medical monitor provided the patient's prognosis is best defined by the extensive-stage small cell lung cancer).
  • Currently pregnant or nursing.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
188 participants (actual)

Study arms

  • Experimental
    Palifosfamide-tris plus Carboplatin and Etoposide

    Drug: palifosfamide-tris in combination with carboplatin and etoposide palifosfamide-tris: 130 mg/m2/day 3 days every 21 days for a max of 6 cycles. carboplatin: AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles. etoposide: 100 mg/m2/day 3 days every 21 days for a max of 6 cycles.

    Drug: Carboplatin · Drug: Palifosfamide-tris · Drug: Etoposide

  • Active comparator
    Carboplatin plus Etoposide

    Drug: carboplatin in combination with etoposide carboplatin: AUC 5mg/mL/min 1 day every 21 days for a maximum of 6 cycles. etoposide: 100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles.

    Drug: Etoposide · Drug: Carboplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Time frame: Assessed every 12 weeks for survival until 1 year following completion of enrollment

Secondary outcomes

  1. Progression Free Survival (PFS)

    Time frame: Assessed every 6 weeks for 22 weeks, then every 12 weeks until progressive disease, initiation of alternate anticancer therapy, or 1 year following the last patient enrolled (whichever is soonest)

  2. Quality of Life (QOL) as Assessed by the EuroQol 5-Dimension 3-Level Questionnaire (EQ-5D-3L) and the European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Module (QLQ-LC13)

    Time frame: Assessed every 3 weeks for 22 weeks, then every 12 weeks until 1 year following the last patient enrolled

  3. Objective Response Rate (ORR)

    Time frame: Assessed every 6 weeks for 22 weeks, then every 12 weeks until a partial or complete response is confirmed

  4. Response Duration

    Time frame: Time from the date of first objective response (partial or complete response), with subsequent confirmation, until the date of disease progression or the occurrence of death

  5. Safety Parameters (Adverse Events and Number of Findings: Physical Examinations, Electrocardiograms [ECGs], Vital Signs, and Clinical Laboratory Results) Using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) 4.03

    Time frame: 22 weeks

07

Study locations

79 sites
  • Birmingham Hematology and Oncology Associates, LLC
    Birmingham, Alabama 35205, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • Redwood Regional Oncology Group
    Santa Rosa, California 95403, United States
  • Christiana Care Health Services
    Newark, Delaware 19713, United States
  • Baptist Cancer Institute
    Jacksonville, Florida 32207, United States
  • Hematology Oncology Associates of the Treasure Coast
    Port Saint Lucie, Florida 34952, United States
  • Peachtree Hematology Oncology Consultants
    Atlanta, Georgia 30318, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Medical and Surgical Specialists, LLC
    Galesburg, Illinois 61401, United States
  • Illinois Cancer Specialists
    Niles, Illinois 60714-5905, United States
  • Central Indiana Cancer Centers
    Fishers, Indiana 46037, United States
  • Goshen Center for Cancer Care
    Goshen, Indiana 46526, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • Horizon Oncology Center
    Lafayette, Indiana 47905, United States
  • Indiana University Health Ball Memorial Hospital
    Muncie, Indiana 47303, United States
  • University of Kansas Hospital
    Overland Park, Kansas 66210, United States
  • Central Baptist Hospital
    Lexington, Kentucky 40503, United States
  • Medical Oncology, LLC
    Baton Rouge, Louisiana 70809, United States
  • Frederick Memorial Hospital Regional Cancer Therapy Center
    Frederick, Maryland 21701, United States
  • Metro Health Cancer Center
    Wyoming, Michigan 49519, United States
  • Saint Mary's Medical Center
    Duluth, Minnesota 55805, United States
  • Virginia Piper Cancer Institute
    Minneapolis, Minnesota 55407, United States
  • John Theurer Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Hematology Oncology Associates of Northern New Jersey, PA, Carol G. Simon Cancer Center
    Morristown, New Jersey 07962, United States
  • University of New Mexico Cancer Center
    Albuquerque, New Mexico 87106, United States
  • New York Oncology Hematology, PC
    Albany, New York 12110-2188, United States
  • Montefiore Medical Center
    The Bronx, New York 10461, United States
  • The Christ Hospital
    Cincinnati, Ohio 45219, United States
  • Dayton Cancer Center, Medical Oncology Hematology Associates
    Dayton, Ohio 45429, United States
  • Medical Oncology Associates Of Wyoming Valley, PC
    Kingston, Pennsylvania 18704, United States
  • Charleston Hematology Oncology Associates, PA
    Charleston, South Carolina 29403, United States
  • Texas Oncology-Medical City Dallas
    Dallas, Texas 75230-6899, United States
  • Texas Oncology- Baylor, Charles A. Sammons Cancer Center
    Dallas, Texas 75246, United States
  • University of Texas Medical Branch at Galveston
    Galveston, Texas 77555-0565, United States
  • Oncology Consultants, PA
    Houston, Texas 77024, United States
  • Texas Oncology, PA
    Wichita Falls, Texas 76310-1610, United States
  • Fletcher Allen Health Care
    Burlington, Vermont 05405, United States
  • Fairfax Northern Virginia Hematology-Oncology, PC
    Fairfax, Virginia 22031, United States
  • Swedish Medical Center
    Seattle, Washington 98104, United States
  • Wisconsin Institutes for Medical Research
    Madison, Wisconsin 53705, United States
  • Southern Medical Day Oncology Care Centre
    Wollongong, New South Wales 2500, Australia
  • CancerCare Manitoba
    Winnipeg, Manitoba R3E 0V9, Canada
  • R. S. McLaughlin Durham Regional Cancer Center at Lakeridge Health Oshawa
    Oshawa, Ontario L1G 2B9, Canada
  • Hôpital Laval
    Sainte-Foy, Quebec G1V 4G5, Canada
  • Centre Hospitalier Lyon Sud
    Pierre Bénité, Auvergne-Rhône-Alpes 69495, France
  • Centre François Baclesse
    Caen, Basse-normandie 14076, France
  • Centre Hospitalier Universitaire -Hôpital Morvan
    Brest, Brittany Region 29200, France
  • Centre Hospitalier Universitaire, Hopital Bretonneau
    Tours, Centre-Val de Loire 97044, France
  • Hôpital du Cluzeau
    Limoges, Limousin, Lorraine 87042, France
  • Institut de Cancérologie de l'Ouest - René Gauducheau
    Saint-Herblain, Pays de la Loire Region 44805, France
  • Hôpital Saint Joseph
    Marseille, Provence-Alpes-Côte d'Azur Region 13008, France
  • Centre Paul Strauss
    Strasbourg, 67085, France
  • Debreceni Egyetem Orvos és Egészségtudományi Centrum
    Debrecen, Hajdú-Bihar, Hungary
  • Mátrai Gyógyintézet
    Mátraháza, Heves County, Hungary
  • Rambam Medical Center
    Haifa, Israel
  • Hadassah Medical Organization, Ein Kerem
    Jerusalem, 91120, Israel
  • Meir Hospital Sapir Medical Center
    Kfar Saba, Israel
  • Western Gallilee Medical Center
    Nahariya, 22100, Israel
  • Rabin Medical Center Beilinson Campus
    Petah Tikva, 49100, Israel
  • Istituto Nazionale per la Ricerca sul Cancro
    Genova, Italy
  • Azienda Ospedaliera Ospedale Niguarda Ca' Granda
    Milan, 20162, Italy
  • Presidio Ospedaliero S. Chiara
    Trento, 38100, Italy
  • Centrum Onkologii - Instytut im. M. Sklodowskiej-Curie w Warszawie
    Warsaw, Masovian Voivodeship, Poland
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, Pomeranian Voivodeship, Poland
  • Wojewódzkie Centrum Onkologii
    Gdansk, Pomeranian Voivodeship, Poland
  • Specjalistyczny Szpital im. Alfreda Sokolowskiego
    Szczecin, West Pomeranian Voivodeship, Poland
  • Republic Clinical Oncology Dispensary of the Ministry of Healthcare of Republic of Bashkortostan
    Ufa, Bashkortostan Republic 450054, Russia
  • City Oncology Hospital # 62
    Moscow Region, Moscow 143423, Russia
  • State Institution of Healthcare "Arkhangelsk Regional Clinical Oncology Dispensary"
    Arkhangelsk, Primorskiy (Maritime) Kray 163045, Russia
  • Republican Clinical Oncologic Dispensary of Ministry of health of Republic Tatarstan
    Kazan', Tatarstan Republic, Russia
  • State Budget Institution of Healthcare "Chelyabinsk Regional Clinical Oncology Dispensary"
    Chelaybinsk, 454087, Russia
  • Ivanovo Regional Oncology Centre
    Ivanovo, Russia
  • Cancer Research Center n.a. N.N. Blokhin
    Moscow, Russia
  • GUZ of Nizhegorodskiy region, Nizhnij Novgorod City Oncology Dispensary
    Nizhny Novgorod, 603081, Russia
  • State Educational Institution "S.M. Kirov Military Medical Academy of Ministry of Defense of Russia"
    Saint Petersburg, 194044, Russia
  • Saint-Petersburg State Medical University n. a. I. P. Pavlov
    Saint Petersburg, Russia
  • State healthcare institution of Yaroslavl region "Regional Clinical Oncologic Hospital"
    Yaroslavl, 150040, Russia
  • China Medical University Hospital
    Taichung, 40447, Taiwan
  • Wythenshawe Hospital
    Manchester, England M23 9LT, United Kingdom
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2012 to primary completion in Dec 2014, 29 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: start May 2012 → Jun 2012, primary completion Jun 2015 → Dec 2014 and completion Jun 2015 → Dec 2014.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2012
First posted
Mar 15, 2012
StartActual
Jun 8, 2012was May 2012
Primary completionActual
Dec 2, 2014was Jun 2015
CompletionActual
Dec 2, 2014was Jun 2015
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Terminated Sponsor closed enrollment in April 2013 following a change in the palifosfamide development plan (business decision), not for safety reasons. Enrolled participants continued treatment and were followed for survival
changed Sep 30, 2026
Sites
20 sites added, 20 sites removed
Show 20 added (5 France, 4 Poland, 4 Russia, 2 United States, 2 Hungary, 1 Canada, 1 Israel, 1 Italy)
  • Hematology Oncology Associates of the Treasure Coast · Port Saint Lucie, United States
  • Montefiore Medical Center · The Bronx, United States
  • Hôpital Laval · Sainte-Foy, Canada
  • Centre Hospitalier Lyon Sud · Pierre Bénité, France
  • Centre Hospitalier Universitaire -Hôpital Morvan · Brest, France
  • Centre Hospitalier Universitaire, Hopital Bretonneau · Tours, France
  • Institut de Cancérologie de l'Ouest - René Gauducheau · Saint-Herblain, France
  • Hôpital Saint Joseph · Marseille, France
  • Debreceni Egyetem Orvos és Egészségtudományi Centrum · Debrecen, Hungary
  • Mátrai Gyógyintézet · Mátraháza, Hungary
  • Rabin Medical Center Beilinson Campus · Petah Tikva, Israel
  • Azienda Ospedaliera Ospedale Niguarda Ca' Granda · Milan, Italy
  • Centrum Onkologii - Instytut im. M. Sklodowskiej-Curie w Warszawie · Warsaw, Poland
  • Uniwersyteckie Centrum Kliniczne · Gdansk, Poland
  • Wojewódzkie Centrum Onkologii · Gdansk, Poland
  • Specjalistyczny Szpital im. Alfreda Sokolowskiego · Szczecin, Poland
  • Republic Clinical Oncology Dispensary of the Ministry of Healthcare of Republic of Bashkortostan · Ufa, Russia
  • State Institution of Healthcare "Arkhangelsk Regional Clinical Oncology Dispensary" · Arkhangelsk, Russia
  • Republican Clinical Oncologic Dispensary of Ministry of health of Republic Tatarstan · Kazan', Russia
  • Saint-Petersburg State Medical University n. a. I. P. Pavlov · Saint Petersburg, Russia
Show 20 removed
  • Hematology Oncology Associates of the Treasure Coast · Port Sant Lucie, United States
  • Montefiore Medical Center · Bronx, United States
  • Hôpital Laval · Sainte Foy, Canada
  • Centre Hospitalier Universitaire -Hôpital Morvan · Brest, France
  • Centre Hospitalier Universitaire, Hopital Bretonneau · Tours cedex 1, France
  • Institut de Cancérologie de l'Ouest - René Gauducheau · Saint Herblain, France
  • Hôpital Saint Joseph · Marseille, France
  • Centre Hospitalier Lyon Sud · Pierre Bénité, France
  • Debreceni Egyetem Orvos és Egészségtudományi Centrum · Debrecen, Hungary
  • Mátrai Gyógyintézet · Mátraháza, Hungary
  • Rabin Medical Center Beilinson Campus · Petah Tiqwa, Israel
  • Azienda Ospedaliera Ospedale Niguarda Ca' Granda · Milano, Italy
  • Centrum Onkologii - Instytut im. M. Sklodowskiej-Curie w Warszawie · Warszawa, Poland
  • Uniwersyteckie Centrum Kliniczne · Gdansk, Poland
  • Wojewódzkie Centrum Onkologii · Gdansk, Poland
  • Specjalistyczny Szpital im. Alfreda Sokolowskiego · Szczecin, Poland
  • Republic Clinical Oncology Dispensary of the Ministry of Healthcare of Republic of Bashkortostan · Ufa, Russian Federation
  • State Institution of Healthcare "Arkhangelsk Regional Clinical Oncology Dispensary" · Arkhangelsk, Russian Federation
  • Republican Clinical Oncologic Dispensary of Ministry of health of Republic Tatarstan · Kazan, Russian Federation
  • Saint-Petersburg State Medical University n. a. I. P. Pavlov · Saint-Petersburg, Russian Federation
Sep 30, 2026
Start date
May 2012→Jun 8, 2012 (actual)
Sep 30, 2026
Primary completion
Jun 2015→Dec 2, 2014 (actual)
Sep 30, 2026
Study completion
Jun 2015→Dec 2, 2014 (actual)
Sep 30, 2026
Enrollment
548 (estimated)→188 (actual)
Sep 30, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedEastern Cooperative Oncology Group (ECOG Performance Status) performance status of 0, 1 or 2.
Oct 1, 2026
Secondary outcomes
2 edited
What changed in the outcomes
  • EditedQuality of Life (QOL) as assessedAssessed by the EuroQol 5-Dimension 3-Level Questionnaire (EQ-5D-3L) and the European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Module (QLQ-LC13)Time frame: Assessed every 3 weeks for 22 weeks, then every 12 weeks until 1 year following the last patient enrolled
  • EditedSafety parametersParameters (numberAdverse Events and Number of adverse events as well as number of findings from physical examinationsFindings: Physical Examinations, Electrocardiograms [ECGs], vital signsVital Signs, and clinical laboratory resultsClinical Laboratory Results)using Using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v.) 4.03Time frame: 22 weeks
Oct 1, 2026
Show all 2 updates
  1. Oct 1, 2026
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedEastern Cooperative Oncology Group (ECOG Performance Status) performance status of 0, 1 or 2.
    Secondary outcomes 2 edited
    What changed in the outcomes
    • EditedQuality of Life (QOL) as assessedAssessed by the EuroQol 5-Dimension 3-Level Questionnaire (EQ-5D-3L) and the European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Module (QLQ-LC13)Time frame: Assessed every 3 weeks for 22 weeks, then every 12 weeks until 1 year following the last patient enrolled
    • EditedSafety parametersParameters (numberAdverse Events and Number of adverse events as well as number of findings from physical examinationsFindings: Physical Examinations, Electrocardiograms [ECGs], vital signsVital Signs, and clinical laboratory resultsClinical Laboratory Results)using Using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v.) 4.03Time frame: 22 weeks
    + 1 other change: description
  2. Sep 30, 2026
    Status unknown→Terminated
    Why stopped Sponsor closed enrollment in April 2013 following a change in the palifosfamide development plan (business decision), not for safety reasons. Enrolled participants continued treatment and were followed for survival
    20 sites added, 20 sites removed
    Show 20 added (5 France, 4 Poland, 4 Russia, 2 United States, 2 Hungary, 1 Canada, 1 Israel, 1 Italy)
    • Hematology Oncology Associates of the Treasure Coast · Port Saint Lucie, United States
    • Montefiore Medical Center · The Bronx, United States
    • Hôpital Laval · Sainte-Foy, Canada
    • Centre Hospitalier Lyon Sud · Pierre Bénité, France
    • Centre Hospitalier Universitaire -Hôpital Morvan · Brest, France
    • Centre Hospitalier Universitaire, Hopital Bretonneau · Tours, France
    • Institut de Cancérologie de l'Ouest - René Gauducheau · Saint-Herblain, France
    • Hôpital Saint Joseph · Marseille, France
    • Debreceni Egyetem Orvos és Egészségtudományi Centrum · Debrecen, Hungary
    • Mátrai Gyógyintézet · Mátraháza, Hungary
    • Rabin Medical Center Beilinson Campus · Petah Tikva, Israel
    • Azienda Ospedaliera Ospedale Niguarda Ca' Granda · Milan, Italy
    • Centrum Onkologii - Instytut im. M. Sklodowskiej-Curie w Warszawie · Warsaw, Poland
    • Uniwersyteckie Centrum Kliniczne · Gdansk, Poland
    • Wojewódzkie Centrum Onkologii · Gdansk, Poland
    • Specjalistyczny Szpital im. Alfreda Sokolowskiego · Szczecin, Poland
    • Republic Clinical Oncology Dispensary of the Ministry of Healthcare of Republic of Bashkortostan · Ufa, Russia
    • State Institution of Healthcare "Arkhangelsk Regional Clinical Oncology Dispensary" · Arkhangelsk, Russia
    • Republican Clinical Oncologic Dispensary of Ministry of health of Republic Tatarstan · Kazan', Russia
    • Saint-Petersburg State Medical University n. a. I. P. Pavlov · Saint Petersburg, Russia
    Show 20 removed
    • Hematology Oncology Associates of the Treasure Coast · Port Sant Lucie, United States
    • Montefiore Medical Center · Bronx, United States
    • Hôpital Laval · Sainte Foy, Canada
    • Centre Hospitalier Universitaire -Hôpital Morvan · Brest, France
    • Centre Hospitalier Universitaire, Hopital Bretonneau · Tours cedex 1, France
    • Institut de Cancérologie de l'Ouest - René Gauducheau · Saint Herblain, France
    • Hôpital Saint Joseph · Marseille, France
    • Centre Hospitalier Lyon Sud · Pierre Bénité, France
    • Debreceni Egyetem Orvos és Egészségtudományi Centrum · Debrecen, Hungary
    • Mátrai Gyógyintézet · Mátraháza, Hungary
    • Rabin Medical Center Beilinson Campus · Petah Tiqwa, Israel
    • Azienda Ospedaliera Ospedale Niguarda Ca' Granda · Milano, Italy
    • Centrum Onkologii - Instytut im. M. Sklodowskiej-Curie w Warszawie · Warszawa, Poland
    • Uniwersyteckie Centrum Kliniczne · Gdansk, Poland
    • Wojewódzkie Centrum Onkologii · Gdansk, Poland
    • Specjalistyczny Szpital im. Alfreda Sokolowskiego · Szczecin, Poland
    • Republic Clinical Oncology Dispensary of the Ministry of Healthcare of Republic of Bashkortostan · Ufa, Russian Federation
    • State Institution of Healthcare "Arkhangelsk Regional Clinical Oncology Dispensary" · Arkhangelsk, Russian Federation
    • Republican Clinical Oncologic Dispensary of Ministry of health of Republic Tatarstan · Kazan, Russian Federation
    • Saint-Petersburg State Medical University n. a. I. P. Pavlov · Saint-Petersburg, Russian Federation
    Start date May 2012→Jun 8, 2012 (now actual)
    Primary completion Jun 2015→Dec 2, 2014 (now actual)
    Study completion Jun 2015→Dec 2, 2014 (now actual)
    Enrollment 548 (estimated)→188 (actual)
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT01555710
Responsible party
Sponsor
First posted
Mar 15, 2012
Start date
Jun 8, 2012
Primary completion
Dec 2, 2014
Completion
Dec 2, 2014
Last update
Oct 1, 2026

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Isophosphamide mustard

Start the discussion